Everything below concerns Metabolite. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-04. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
This is a book born out of frustration. This is a book born out of hope. It attempts to speak for no one and give voice to many. This is a book that could have emerged without ‘Hillbilly Elegy,’ but it was also created in the explicit context of a post-election, post-‘Hillbilly Elegy’ moment. It therefore attempts to respond to those who have felt they understand Appalachia ‘now that they have read Hillbilly Elegy’ and to push back and complicate those understandings. Author Zane McNeill described how media narratives arising from Hillbilly Elegy felt like they erased the stories of queer Appalachians. McNeill didn't feel the community was represented in literature until the 2018 publication of the Electric Dirt zine. It was produced by the Queer Appalachia collective, and shared writing about queer and trans experiences in the region. Its popularity sparked more works on queer Appalachian studies. Barbara Kingsolver felt a sense of duty to combat Vance's portrayal of Appalachian life and media stereotypes of the region with a story that she felt was more authentic. As her reaction, she wrote the Pulitzer Prize-winning Demon Copperhead to be a "great Appalachian novel". Kingsolver criticized Hillbilly Elegy as relying on "the same old victim-blaming trope. It was like a hero story: 'I got out of here, I went to Yale. But those lazy people, you know, just don't have ambitions. They don't have brains.
Another key to finding the correct structure of DNA was the so-called Chargaff ratios, experimentally determined ratios of the nucleotide subunits of DNA: the amount of guanine is equal to cytosine and the amount of adenine is equal to thymine. A visit by Erwin Chargaff to England, in 1952, reinforced the salience of this important fact for Watson and Crick. The significance of these ratios for the structure of DNA were not recognised until Watson, persisting in building structural models, realised that A:T and C:G pairs are structurally similar. In particular, the length of each base pair is the same. Chargaff had also pointed out to Watson that, in the aqueous, saline environment of the cell, the predominant tautomers of the pyrimidine (C and T) bases would be the amine and keto configurations of cytosine and thymine, rather than the imino and enol forms that Crick and Watson had assumed. They consulted Jerry Donohue who confirmed the most likely structures of the nucleotide bases. The base pairs are held together by hydrogen bonds, the same non-covalent interaction that stabilise the protein α-helix. The correct structures were essential for the positioning of the hydrogen bonds. These insights led Watson to deduce the true biological relationships of the A:T and C:G pairs.
=== Pioneering hydroxamate structures === The first generation of MMP inhibitors were based on the structure of the collagen molecule. In the design of these inhibitors, the basic protein backbone of collagen is maintained but the amide bond is replaced with a zinc-binding group. This group of inhibitors contain a hydroxamate (-CONHOH) group that binds the zinc atom in the active site of the MMP enzyme, therefore this group is called "hydroxamate-based MMP inhibitors“. An example can be seen in Marimastat, a first generation inhibitor, which has a similar backbone and sidechain format to collagen.
Moreover, the absolute uranium concentrations indicate that there was no contamination of the earthworm species studied." Though a more comprehensive assessment is possible, a 2011 update on a cancer scare regarding Italian soldiers who had served in the Balkans found lower than expected incidence rates for all cancers, a finding "consistent with lacking evidence of an increased cancer incidence among troops of other countries deployed in the areas of Iraq, Bosnia, and Kosovo, where armour-penetrating depleted uranium shells have been used." In 2018, Serbia set up a commission of inquiry into the consequences of the use of depleted uranium during the 1999 NATO bombing of Yugoslavia in southern Serbia and its link to the rise of diseases and tumors among citizens, particularly in young children born after 1999. Zoran Radovanovic, an epidemiologist and the chairman of the Serbian Medical Association's ethics committee, denied that there had been a rise in cancer cases in areas where bombings had taken place. He continued by saying that Serbians frequently worry about a cancer epidemic that does not exist. NATO has repeatedly claimed that depleted uranium found in the ammunition used in the 1999 bombardments cannot be linked to adverse health effects.
Sources: en.wikipedia.org
== See also == Houses of Parliament, Cape Town List of acts of the Parliament of South Africa Politics of South Africa List of legislatures by country List of committees of the Parliament of South Africa Provincial legislatures of South Africa
=== Pregnancy === When given in the second or third trimesters of pregnancy, no artesunate-related adverse pregnancy outcomes have been reported. However, there is insufficient evidence regarding the safety of artesunate use in the first trimester of pregnancy. The WHO recommends that artesunate use for severe malaria in the first trimester should be based on the individual risks versus benefits. In absence of other viable treatment options, artesunate may be used.
=== Post-traumatic stress disorder === Witnessing a devastating or terrifying situation can lead to post-traumatic stress disorder (PTSD). This mental health condition triggers anxiety, depression, and extreme fear with memories. Intranasal administration of temperature-sensitive hydrogels loaded with PTSD medications showed enhanced brain targeting effects and tissue distribution. Similarly, another study observed anti-PTSD effects with intranasal administration of loaded hydrogels.
== Career == In 2001, Strahl joined the University of North Carolina at Chapel Hill as an assistant professor in the Department of Biochemistry and Biophysics. He was promoted to associate professor in 2008 and full professor in 2014. He also holds an appointment at UNC’s Lineberger Comprehensive Cancer Center and is a faculty member in the Curriculum in Genetics and Molecular Biology. Additionally, Strahl also serves as the faculty director of the UNC High-Throughput Peptide Synthesis and Array Core Facility From 2016 to 2020, he served as the Vice Chair of the Department of Biochemistry & Biophysics at UNC. From 2020 to 2022, he stepped into the role of Interim Chair of Biochemistry and Biophysics. Since 2023, Strahl has held the position of Assistant Dean for Research in the Office of Research at the University of North Carolina School of Medicine. The primary mission of the Office of Research is to develop and implement a strategic plan for research in the School of Medicine(reference). The UNC School of Medicine selected Strahl as an Oliver Smithies Investigator in recognition of his research contributions. This annual award recognizes senior faculty members who have gained international recognition for their work. Since 2015, Strahl has directed UNC's Program on Chromatin and Epigenetics, aiming to understand the complex language of epigenetic regulation. The program seeks to advance human health and address diseases. Stahl is also co-founder of EpiCypher, Inc. – a company known for services for chromatin biology and epigenetics research.
== Availability == 6-MAM is rarely encountered in an isolated form due to the difficulty in selectively acetylating morphine at the 6-position without also acetylating the 3-position. However, it is found in significant amounts in black tar heroin along with heroin itself.
Sources: en.wikipedia.org
=== Pharmacokinetics === Sirolimus is metabolized primarily by the CYP3A4 enzyme (about 90%), and to a lesser degree by CYP3A5 and CYP2C8. It is also a substrate of the P-glycoprotein (P-gp) efflux pump. It has linear pharmacokinetics. In studies on N=6 and N=36 subjects, peak concentration was obtained in 1.3 hours +/r- 0.5 hours and the terminal elimination was slow, with a half life around 60 hours +/- 10 hours. Sirolimus was not found to effect the concentration of ciclosporin, which is also metabolized primarily by the CYP3A4 enzyme. The bioavailabiliy of sirolimus is low, and the absorption of sirolimus into the blood stream from the intestine varies widely between patients, with some patients having up to eight times more exposure than others for the same dose. Drug levels are, therefore, taken to make sure patients get the right dose for their condition. This is determined by taking a blood sample before the next dose, which gives the trough level. However, good correlation is noted between trough concentration levels and drug exposure, known as area under the concentration-time curve, for both sirolimus (SRL) and tacrolimus (TAC) (SRL: r2 = 0.83; TAC: r2 = 0.82), so only one level need be taken to know its pharmacokinetic (PK) profile. PK profiles of SRL and of TAC are unaltered by simultaneous administration. Dose-corrected drug exposure of TAC correlates with SRL (r2 = 0.8), so patients have similar bioavailability of both.
Peitzmeier and colleagues conducted a study on partner violence; they found that transgender individuals are 3 times more likely than their counterparts to experience partner violence physical and sexual. Partner violence is a risk factor for numerous health outcomes like a decrease psychological well-being, a poor sexual health, etc. There is limited data regarding the impact of social determinants of health on transgender and gender non-conforming individuals' health outcomes. However, despite the limited data available, transgender and gender non-conforming individuals have been found to be at higher risk of experiencing poor health outcomes and restricted access to health care due to increased risk for violence, isolation, and other types of discrimination both inside and outside the health care setting. Despite its importance, access to preventive care is also limited by several factors, including discrimination and erasure. A study on young transgender women's access to HIV treatment found that one of the main contributors to not accessing care was the use of incorrect name and pronouns. A meta analysis of the National Transgender Discrimination Survey examined respondents who used the "gender not listed here" option on the survey and their experiences with accessing health care. Over a third of the people who chose that option said that they had avoided accessing general care due to bias and fears of social repercussions.
Disposal of this waste is an environmental concern, as many medical wastes are classified as infectious or biohazardous and could potentially lead to the spread of infectious disease. The most common danger for humans is the infection which also affects other living organisms in the region. Daily exposure to the wastes (landfills) leads to accumulation of harmful substances or microbes in the person's body. A 1990 report by the United States Agency for Toxic Substances and Disease Registry concluded that the general public is not likely to be adversely affected by biomedical waste generated in the traditional healthcare setting. They found, however, that biomedical waste from those settings may pose an injury and exposure risks via occupational contact with medical waste for doctors, nurses, and janitorial, laundry and refuse workers. Further, there are opportunities for the general public to come into contact with medical waste, such as needles used illicitly outside healthcare settings, or biomedical waste generated via home health care.
== Add-ons == As a real-time trace gas analysis method based on mass spectrometry, PTR-MS has two obvious limitations: Isomers cannot be easily separated (for some it is possible by switching the reagent ions or by changing the reduced electric field strength in the drift tube) and the sample has to be in the gas phase. Countermeasures against these limitations have been developed in the form of add-ons, which can either be installed into the PTR-MS instrument or operated as external devices.
Vegetables play an important role in human nutrition. Most are low in fat and calories but are bulky and filling. They supply dietary fiber and are important sources of essential vitamins, minerals, and trace elements. Particularly important are the antioxidant vitamins A, C, and E. When vegetables are included in the diet, there is found to be a reduction in the incidence of cancer, stroke, cardiovascular disease, and other chronic ailments. Research has shown that, compared with individuals who eat less than three servings of fruits and vegetables each day, those that eat more than five servings have an approximately twenty percent lower risk of developing coronary heart disease or stroke. The nutritional content of vegetables varies considerably; some contain useful amounts of protein though generally they contain little fat, and varying proportions of vitamins such as vitamin A, vitamin K, and vitamin B6; provitamins; dietary minerals; and carbohydrates. The consumption of crunchy and hard to chew foods, such as raw vegetables, during youth, while the bones are still growing, is needed for the human's, and other animals', jaws' proper development, and without their consumption, the jaws do not grow to their full size, thus not leaving enough room for the teeth to grow in correctly, causing crooked and impacted teeth. However, vegetables often also contain toxins and antinutrients which interfere with the absorption of nutrients.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.